AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Prep: Cook: Serves:

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease.

The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year.

Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

Last Month

Next Month

Go Back

Share this story

Comments

Advances

Fast-acting inhalable levodopa produces positive results in clinical trial

Is inhalable levodopa for treating Parkinson’s one step closer?

Ask the expert: How can hallucinations affect people with Parkinson’s?

Professor Per Odin shares need-to-know information on the symptom

Indian Ocean Row 2018: the story so far

An update on the four men rowing 3,600 miles for Parkinson’s

Could certain cancers be linked to Parkinson’s disease?

Previous research has suggested that people with Parkinson’s may generally be less likely to develop most cancers. However, a new international study has found a potential genetic link between certain types of cancer and the condition. The team analysed genetic data from genome-wide association studies – a research approach that aims to identify gene variations associated with disease risk – to recognise common genetic risk factors between cancer and Parkinson’s. The findings uncovered a genetic link between the condition and both prostate cancer and melanoma. Meanwhile, the sum of various gene variants (otherwise known as the polygenic risk score) that contribute to Parkinson’s was significantly associated with a higher risk of breast cancer. “Our results suggest the importance of shared genetic variants between Parkinson’s and some cancers,” the researchers concluded in the study, which was published in the medical journal ‘Movement Disorders’. They highlighted the need for further studies to…

Investigational Parkinson’s disease dementia therapy fails in clinical trial

Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase. This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study. The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function. Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did…

A new intimacy guide aims to support people with Parkinson’s disease in the US

Does sexual wellness in the Parkinson’s community need more focus? It’s an area that the American Parkinson Disease Association (APDA) and media brand Havas Health Plus have targeted through the launch of a free intimacy guide. Available to people in the US, ‘The ParkinSex Booklet & Kit’ aims to support those whose relationships may have been impacted by emotional and physical distance linked to the condition. Alongside an educational guide, the kit includes items such as candles, coupons for adaptative clothing and massage stones. Following a positive response to an initial pilot distribution of the guides in the US, there is now a waitlist for future kits. Commenting on the launch in a press release, APDA president and CEO Leslie Chambers said: “The challenges of Parkinson’s can often result in intimacy and connection getting left behind. This is why we created ‘The ParkinSex Booklet & Kit’, to help people with…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Advances

Fast-acting inhalable levodopa produces positive results in clinical trial

Special reports

Ask the expert: How can hallucinations affect people with Parkinson’s?

Global update

Indian Ocean Row 2018: the story so far

Could certain cancers be linked to Parkinson’s disease?

Investigational Parkinson’s disease dementia therapy fails in clinical trial

A new intimacy guide aims to support people with Parkinson’s disease in the US

{title}

Subscribe

AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Last Month

Next Month

Share this story

Comments

Related articles

Advances

Fast-acting inhalable levodopa produces positive results in clinical trial

Special reports

Ask the expert: How can hallucinations affect people with Parkinson’s?

Global update

Indian Ocean Row 2018: the story so far

Could certain cancers be linked to Parkinson’s disease?

Investigational Parkinson’s disease dementia therapy fails in clinical trial

A new intimacy guide aims to support people with Parkinson’s disease in the US

{title}

Subscribe

Sign in